meningococcal

  1. T

    Novartis Phase III Study Shows Meningococcal B Vaccine Candidate Could Be First To Pr

    New data presented by Novartis Vaccines involving thousands of babies indicates that an investigational vaccine has the potential to be the first broad-coverage vaccine against the deadly meningococcal B (meningitis B) disease. 1 There is currently no broad-protection vaccine available...
Back
Top